BRIEF-BridgeBio Pharma Says Acoramidis Reduces CVM Or CVH Risk By 49% Through Month 30

Reuters
Sep 28
BRIEF-<a href="https://laohu8.com/S/BBIO">BridgeBio Pharma</a> Says Acoramidis Reduces CVM Or CVH Risk By 49% Through Month 30

Sept 28 (Reuters) - BridgeBio Pharma Inc BBIO.O:

  • ACORAMIDIS BEGINS TO REDUCE CUMULATIVE CARDIOVASCULAR OUTCOMES WITHIN THE FIRST MONTH OF TREATMENT IN PATIENTS WITH ATTR-CM

  • BRIDGEBIO PHARMA INC - ACORAMIDIS REDUCES CVM OR CVH RISK BY 49% THROUGH MONTH 30

Source text: ID:nGNX4yHZDw

Further company coverage: BBIO.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10